<DOC>
	<DOC>NCT01248325</DOC>
	<brief_summary>Sixty subjects will take part in this study. The subjects will be randomly assigned in a 1:1 ratio between the two arms of study. (Group A: Solution of Luffa Nasal Operculate 5mg/mL, Group B: saline). The subjects will use the study medication or comparative, according to their randomization, for a treatment period of 3 to 7 days. A follow-up visit will be made 15 days after initiation of treatment.</brief_summary>
	<brief_title>A Study of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline (NaCl 09%) for the Relief of Nasal Obstruction</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Obstruction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Subjects of both sexes aged over 18 years. Presence of nasal congestion due to colds, rhinitis, influenza, sinusitis and acute or chronic sinusitis Sign the Informed Consent Form Comply the study requirements and attend to study visits Female subjects must have a NEGATIVE urine pregnancy test during the screening. Known allergy to any study product component Subject pregnant, lactating or of childbearing potential and not using adequate and effective contraceptive Vasoconstrictor nasal topic or oral Use of a decongestant nasal whatever the route of administration Use of intranasal corticosteroids Use of antiallergic Use of medication containing atropine Subjects that are participating in another study or who participated in another study, less than 12 months Any subjects deemed unsuitable for study by the Principal Investigator Abuse of alcohol or illicit drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>